Valuation: MaaT Pharma

Market Cap 52.57M 60.55M 49.02M 45.03M 85.16M 5.76B 86.1M 578M 226M 2.88B 227M 222M 9.54B P/E 2026 *
-1.46x
P/E 2027 * -2.51x
Enterprise Value 63.88M 73.57M 59.56M 54.71M 103M 7B 105M 702M 274M 3.5B 276M 270M 11.59B EV / Sales 2026 *
6.55x
EV / Sales 2027 * 3.02x
Free-Float
36.85%
Yield 2026 *
-
Yield 2027 * -
1 week-0.36%
Current month+0.36%
1 month-3.12%
3 months-52.55%
6 months-61.36%
Current year-42.00%
1 week 2.76
Extreme 2.765
2.86
1 month 2.6
Extreme 2.6
2.94
Current year 2.32
Extreme 2.32
8.62
1 year 2.32
Extreme 2.32
8.62
3 years 2.32
Extreme 2.32
9.96
5 years 2.32
Extreme 2.32
14.4
10 years 2.32
Extreme 2.32
14.4
Manager TitleAgeSince
Chief Executive Officer - 2013-12-31
Director of Finance/CFO 59 2024-10-31
Chief Tech/Sci/R&D Officer - 2024-06-23
Director TitleAgeSince
Director/Board Member - 2013-12-31
Director/Board Member 57 2013-12-31
Chairman - 2015-12-31
Date Insider Type Main position Quantity % Market Cap.
1/29/26
Seventure Partners SA
SellCompany 25,423 0.1356%
1/28/26
Seventure Partners SA
SellCompany 57,964 0.3091%
1/14/26
Seventure Partners SA
SellCompany 4,755 0.0254%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.36%-52.71%-55.71% 60.55M
+10.00%+14.90%+53.89%+87.07% 62.53B
+0.80%-5.70%+23.89%+62.65% 52.43B
-0.98%-1.19%-16.98%-14.21% 23.1B
+0.30%-5.17%-11.23%+349.07% 21.4B
+1.73%-1.57%+32.81%-25.80% 17.76B
+4.29%+8.97%+200.03%+341.85% 15.47B
+2.32%-0.52%+14.32%+617.39% 14.68B
+1.71%-0.90%+52.13%+176.27% 14.08B
+4.16%+4.44%+444.12%+183.06% 12.62B
Average +2.48%+0.85%+74.03%+172.16% 23.41B
Weighted average by Cap. +3.69%+1.83%+60.70%+147.58%

Financials

2026 *2027 *
Net sales 9.75M 11.23M 9.09M 8.35M 15.79M 1.07B 15.97M 107M 41.9M 534M 42.17M 41.25M 1.77B 28.88M 33.26M 26.92M 24.73M 46.78M 3.16B 47.29M 317M 124M 1.58B 125M 122M 5.24B
Net income -31.69M -36.5M -29.55M -27.15M -51.34M -3.47B -51.9M -348M -136M -1.74B -137M -134M -5.75B -15.31M -17.63M -14.28M -13.11M -24.8M -1.68B -25.07M -168M -65.79M -838M -66.22M -64.77M -2.78B
Net Debt 11.3M 13.02M 10.54M 9.68M 18.31M 1.24B 18.51M 124M 48.58M 619M 48.89M 47.82M 2.05B 34.5M 39.73M 32.17M 29.55M 55.88M 3.78B 56.5M 379M 148M 1.89B 149M 146M 6.26B
Logo MaaT Pharma
MaaT Pharma is a late-stage biotechnology company and a leader in the development of intestinal microbiota-based drugs designed to modulate the immune system of cancer patients and improve their survival. A pioneer in its field, MaaT Pharma is developing the first immunomodulatory drug candidate based on intestinal microbiota in oncology, currently in phase 3 clinical evaluation. Thanks to its proprietary pooling (combining donations of healthy microbiota) and microbial co-culture technologies, MaaT Pharma is developing standardised drugs with high bacterial diversity, aimed at improving the survival of cancer patients.
Employees
56
Date Price Change Volume
26-08-04 €2.790 0.00% 10,941
26-08-03 €2.790 +0.36% 20,686
26-07-31 €2.780 -0.54% 19,989
26-07-30 €2.795 +0.18% 23,151
26-07-29 €2.790 -0.36% 10,675
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.790EUR
Average target price
6.500EUR
Spread / Average Target
+132.97%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MAAT Stock